News

benzinga_article
2025.11.10 16:47
Vera Therapeutics shares are trading higher after the company announced its ORIGIN Phase 3 trial met its primary endpoint. HC Wainwright maintained a Buy rating on the stock and raised its price target from $85 to $90.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.